Abstract: As one of the most common microvascular complications of diabetes, diabetic kidney disease is not only the leading cause of end-stage renal disease(ESRD) in developed countries, but also the second cause of ESRD in China.In recent years, a number of clinical trials attempting to prove the beneficial of intensive glucose control indicated that intensive blood glucose control therapy has the effect of improving urinary protein in different groups of patients.However, there exist the risks of hypoglycemia and cardiovascular diseases simultaneously.Thus, the risk reward ratio of intensive blood glucose control is still debatable.In this paper, we discuss the individualized treatment, the timing of intervention, the target of intensive glucose control therapy, and some other issues related to the results of these clinical trials.